A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's Disease
ISRCTN | ISRCTN96337233 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN96337233 |
Secondary identifying numbers | N/A |
- Submission date
- 06/11/2002
- Registration date
- 06/11/2002
- Last edited
- 28/10/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English Summary
Not provided at time of registration
Contact information
Prof Richard Gray
Scientific
Scientific
University of Birmingham Clinical Trials Unit
University of Birmingham
Park Grange
1 Somerset Road
Edgbaston
Birmingham
B15 2RR
United Kingdom
Phone | +44 (0)121 415 9100 |
---|---|
r.gray@bham.ac.uk |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Scientific title | A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's Disease |
Study acronym | AD2000 |
Study hypothesis | To assess the efficacy and safety of donepezil and aspirin in Alzheimer's Disease. |
Ethics approval(s) | Not provided at time of registration |
Condition | Alzheimer's disease |
Intervention | Patients are randomised to receive donepezil 5 mg or placebo for the first 12 weeks of the trial. Those who complete 12 weeks of treatment are re-randomised to receive 48 weeks of donepezil or placebo from week 13 onwards, with donepezil dose sub-randomised between 5 and 10 mg. Eligible patients (those with no clear indication for, or clear indication against, aspirin) are also randomised at entry between 75 mg enteric-coated aspirin daily or aspirin avoidance. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Applicable |
Drug / device / biological / vaccine name(s) | Donepezil, aspirin |
Primary outcome measure | 1. Cognition (assessed with the mini-mental state examination [MMSE]) 2. Functional ability (assessed with the Bristol activities of daily living scale [BADLS]) Patients were assessed at 12-week intervals in the first year and once each year thereafter. |
Secondary outcome measures | 1. Time to formal domiciliary or institutional care 2. Progress of disability 3. Behavioural symptoms 4. Caregiver wellbeing 5. Care time Patients were assessed at 12-week intervals in the first year and once each year thereafter. |
Overall study start date | 01/01/2000 |
Overall study end date | 01/01/2004 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Not Specified |
Sex | Both |
Target number of participants | 310 |
Participant inclusion criteria | 1. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM IV) diagnosis of Alzheimer's disease, with or without evidence of vascular dementia 2. Mild to moderate Alzheimer's disease (Mini Mental State Examination [MMSE] score 10 - 26) 3. No definite contraindication to, or clear indication for, donepezil 4. Not in residential care 5. Regular carer 6. Not have already taken donepezil or any other cholinergic enhancing agent |
Participant exclusion criteria | Not provided at time of registration |
Recruitment start date | 01/01/2000 |
Recruitment end date | 01/01/2004 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
University of Birmingham Clinical Trials Unit
Birmingham
B15 2RR
United Kingdom
B15 2RR
United Kingdom
Sponsor information
West Midlands NHS Research & Development Executive (UK)
Government
Government
Bartholomew House
142 Hagley Road
Birmingham
B16 9PA
United Kingdom
Website | http://www.doh.gov.uk/research/wmro/new.htm |
---|
Funders
Funder type
Government
West Midlands NHS Research & Development Executive (UK)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan | Not provided at time of registration |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | 26/06/2004 | Yes | No | ||
Results article | 01/01/2008 | Yes | No |
Editorial Notes
28/10/2022: Internal review.